This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. We found that GluN2A N615K resulted in block by Mg 2+ 1 mmol/L being greatly reduced (89% vs 8%), block by memantine 10 μmol/L (76% vs 27%) and amantadine 100 μmol/L (45% vs 17%) being substantially reduced, block by ketamine 10 μmol/L being modestly reduced (79% vs 73%) and block by dextromethorphan 10 μmol/L being enhanced (45% vs 55%). Coapplying Mg 2+ with memantine or amantadine did not reduce the GluN2A N615K block seen with either small molecule. In addition, we measured single-channel conductance of GluN2A
N615K
(GRIN2A C1845A ) in two unrelated individuals with severe epileptic encephalopathy.
This missense variant substitutes a lysine in place of an asparagine known to be important for blockade by Mg 2+ and other small molecule channel blockers. We therefore measured the impact of GluN2A N615K on a range of NMDA receptor channel blockers using two-electrode voltage clamp recordings made in Xenopus oocytes.
We found that GluN2A N615K resulted in block by Mg 2+ 1 mmol/L being greatly reduced (89% vs 8%), block by memantine 10 μmol/L (76% vs 27%) and amantadine 100 μmol/L (45% vs 17%) being substantially reduced, block by ketamine 10 μmol/L being modestly reduced (79% vs 73%) and block by dextromethorphan 10 μmol/L being enhanced (45% vs 55%). Coapplying Mg 2+ with memantine or amantadine did not reduce the GluN2A N615K block seen with either small molecule. In addition, we measured single-channel conductance of GluN2A
-containing NMDA receptors in outside-out patches pulled from Xenopus oocytes, finding a 4-fold reduction in conductance (58 vs 15 pS). In conclusion, the GluN2A N615K variant is associated with substantial changes to important physiological and pharmacological properties of the NMDA receptor. Our findings are consistent with GluN2A N615K having a diseasecausing role, and inform potential therapeutic strategies.
K E Y W O R D S
blocker, channel, epilepsy, human, magnesium, mutation, NMDA, receptor, variant is associated with a severe phenotype of early onset epileptic encephalopathy in two unrelated individuals. 8, 9 It substitutes a lysine (positively charged) for an asparagine (neutral) in the M2 region of the NMDA receptor pore, in one of the narrowest regions of the pore. 10 The residue affected is the most important determinant of Mg 2+ block in GluN2A subunits: the "N + 1" site (an asparagine that neighbors the QRN site asparagine in GluN2A).
| INTRODUC TI ON
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Previous work has shown that the GluN2A N615K variant has profound effect on NMDA receptor properties: it reduces block by Mg 2+4,9,12 and influences block by other channel blockers, 4 it reduces calcium permeability 9 and it reduces single-channel conductance. 12 Importantly, the variant influences receptor properties even when only one copy is present in a receptor. 12 Some of these effects could be viewed as "gain of function", some "loss of function". Seeking to reverse the "gain of function" component could be aided by the use of channel blockers, as has been trialed successfully by the use of memantine in a child carrying a different GRIN2A variant. 4 To do this, detailed knowledge of the effect of channel blockers on receptors containing the GluN2A N615K variant in physiological contexts is required.
In this study we therefore sought to replicate and extend previous work demonstrating a reduced potency of memantine and amantadine, 4 by investigating the degree of inhibition by these blockers in the presence and absence of physiological concentrations of Mg
2+
. We examined the previously uninvestigated blocker ketamine. In addition, we replicated our previous finding of a reduction in single-channel conductance 12 in a different system using a 
| cRNA synthesis and expression in oocytes
The cDNA for wild type human NMDA subunit GluN1-1a (hereafter GluN1) and GluN2A (GenBank accession codes: NP_015566, NP_000824) 13 were gifts from Dr Hongjie Yuan (University of Emory). All cDNAs were in pCI-neo. Site-directed mutagenesis to generate GluN2A N615K was performed as described previously 12 using a mutagenizing polymerase chain reaction, recircularization and transformation. The mutation was verified using Sanger sequencing through the mutated region.
cRNA synthesis and expression was performed as described previously. 14 cRNA for wild type and mutant subunits was synthesized from Recordings were made 48-96 hours post injection. Patches were voltage-clamped at -60 or -100 mV. unless otherwise stated. Correction for multiple comparisons were made using the Bonferroni method. The significance level used was P < 0.05. In figures, * indicates P < 0.05, ** indicates P < 0.01 and *** indicates P < 0.001.
| Measurements made
| Two-electrode voltage-clamp recordings
| Data analysis and statistical procedures
| Compliance with design and statistical analysis requirements
Oocytes were randomly allocated for injection with either WT or mutant cDNA. The experimenter was not blinded to construct as this was thought unlikely to influence the electrophysiological recordings. All n refer to number of oocytes, not number of traces. Although groups were designed to have equal n values, application of exclusion rules following recording (see above) meant that groups ended up unequal in size. The t-tests used for comparisons adjust for resulting unequal variance. In the case of single-channel recordings the n numbers reported are less than 5 but data obtained are highly consistent.
| Drugs, reagents and other materials
Memantine, amantadine, ketamine, and dextromethorphan were purchased from Tocris Bioscience (Bristol, UK). The remaining substances were purchased from Sigma-Aldrich (St Louis, MO). Figure 2C,D) . In contrast to the other channel blockers, the maximal inhibition by dextromethorphan was modestly increased by the presence of the GluN2A N615K variant (Figure 2D-F) .
| RE SULTS
| GluN2A
N615K reduces single-channel conductance
In view of the profound influence of the GluN2A N615K mutation on channel blockade we next assessed the variant's impact on ion permeation. In outside-out patches pulled from oocytes expressing
GluN2A
WT or GluN2A N615K -containing NMDA receptors we identified a 4-fold reduction in single-channel conductance (Figure 3 ).
| D ISCUSS I ON
| GluN2A
N615K influences degree of blockade by
NMDA receptor channel blockers
We found that GluN2A N615K reduced the inhibition caused by the small molecule channel blockers memantine, amantadine and ketamine, while increasing the inhibition caused by dextromethorphan. A two-way repeated measures ANOVA (blocker as within subjects factor, subunit as between subjects factor) showed a significant main effect of channel blocker (F 2,39 = 26.1, P = 6.4E-8) and of subunit (F 1,39 = 588.3, P < 2E-16) with a significant two-way interaction (F 2,39 = 7.3, P = 0.002). Planned post -hoc Bonferroni corrected independent Welch t-tests showed that GluN2A N615K was associated with lower blockade by memantine (WT: 76 ± 1%, N615K: 27 ± 2%, t 10.1 = 17.1, P = 4.9E-8), by Mg 2+ (WT: 89 ± 1%, N615K: 8 ± 3%, t 7.4 = 23.2, P = 1.8E-7) and by the two combined (WT: 94 ± 1%, N615K: 29 ± 4%, t 6.4 = 15.7, P = 1.2E-5). Planned post-hoc Bonferroni corrected paired t-tests showed that combining memantine and Mg 2+ led to a higher degree of block in oocytes expressing GluN2A WT subunits t 8 = 17.5, P = 5.8E-7) but not in those expressing GluN2A N615K subunits (t 6 = 1.4, P > 0.2) (WT: n = 9 oocytes, N615K: n = 7 oocytes). D, Summary data showing percentage inhibition by amantadine (100 μmol/L), Mg 2+ (1 mmol/L) and the two combined for oocytes transfected with either
GluN2A
WT or GluN2A N615K -containing NMDA receptors, voltage-clamped at -60 mV. A two-way repeated measures ANOVA (blocker as within subjects factor, subunit as between subjects factor) showed a significant main effect of channel blocker (F 2,39 = 146.5, P < 2E-16) and of subunit (F 1,39 = 481.8, P < 2E-16) with a significant two-way interaction (F 2,39 = 20.0, P = 1E-6). Planned post-hoc Bonferroni corrected independent Welch t-tests showed that GluN2A N615K was associated with lower blockade by amantadine (WT: 45 ± 4%, N615K: 17 ± 1%, t 10.3 = 7.3, P = 2.2E-5), by Mg 2+ (WT: 88 ± 1%, N615K: 6 ± 1%, t 13.7 = 39.9, P = 7.0E-15) and by the two combined (WT: 91 ± 1%, N615K:
20 ± 4%, t 7.2 = 19.2, P = 1.4E-15). Planned post-hoc Bonferroni corrected paired t-tests showed that combining memantine and Mg 2+ led to a higher degree of block in oocytes expressing GluN2A WT subunits (t 8 = 14.5, P = 2.5E-6) but not in those expressing GluN2A N615K subunits (t 6 = 1.2, P > 0.3) (WT: n = 9 oocytes, N615K: n = 7 oocytes)
This is consistent with previous work 4 and with work identifying overlap between residues important for Mg 2+ block and residues important for binding of memantine 10, 15 and ketamine. 16 Amantadine is structurally very similar to memantine so is likely to interact with similar residues. In contrast, dextromethorphan's primary metabolite dextrorphan interacts with residues in the more extracellular portion of the vestibule. 17 Our data suggest that this interaction is nonetheless altered by the GluN2A N615K variant deeper in the receptor pore. This may be of potential therapeutic relevance as dextromethorphan is already licensed for use in humans (it is a common ingredient in cough medicines). However, the enhanced block of GluN2A N615K -containing receptors by dextromethorphan would only be of benefit if the primary problem caused by the variant was receptor hyperfunction, rather than hypofunction. Our findings and previous work show that the variant is associated with alterations in receptor properties which could potentially lead to either outcome, so this would need to be investigated cautiously. Further, the increase in block in GluN2A N615K -containing receptors is modest, meaning that the effects of any given dose of dextromethorphan on wild type receptors would also need to be considered and could potentially be harmful.
We also found that coapplying Mg 2+ with the channel blockers memantine and amantadine had no effect on the maximal GluN2A N615K block observed with the small molecules. This suggests that these drugs could still be expected to cause some block of GluN2A N615K -containing NMDA receptors in vivo, but that they would cause more block at wild type receptors. This would likely limit their therapeutic utility, unless compensatory processes in some way caused wild type NMDA receptor overactivation. Our finding that wild type subunits show higher block when memantine or amantadine are coapplied with Mg 2+ than when either are applied alone is consistent with work done in the same system with the same concentrations of blocker used. N615K -containing NMDA receptors, voltage-clamped at -60 mV. An independent Welch t-test showed that GluN2A N615K was associated with an increase in block (WT: 45 ± 2 (n = 7 oocytes), N615K: 55 ± 3 (n = 8 oocytes), t 12.6 = 2.8, P = 0.015)
conductance value obtained here using technically "gold standard"
outside-out patches is in good agreement with that obtained using cell-attached patches containing GluN2A N615K diheteromeric receptors expressed in human embryonic kidney (HEK293T) cells.
12
The reduction in cation conductance seen likely reflects the introduction of a positively charged residue at a constriction of the pore. 10 This region has already been shown to determine conductance by mutation studies in GluN1 and GluN2B subunits. [19] [20] [21] The reduction in conductance is likely to disrupt the receptor's ionotropic signaling function and thus potentially impair both neurotransmission and plasticity. However, a reduction in conductance is unlikely to be amenable to therapeutic modification by existing small molecules.
In conclusion, this study found that the human disease-associated variant GluN2A N615K has marked effects on inhibition by channel blockers and single-channel conductance. The channel blocker dextromethorphan is a potential candidate for possible therapeutic use. 
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